AUPH Stock — Aurinia Pharmaceuticals Inc: Cash, EV, Pipeline

What they do

Background Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”).

Source: 10-K FY2025 via SEC EDGAR

Share price

$16.46

Market cap

$2,205.6M

Cash

$45.6M

Enterprise value

$2,160.0M

Balance sheet

Cash	$45.6M
Debt	$0.0M
Net cash	$45.6M
Enterprise value	$2,160.0M
Basic shares	134.0M shares
Fully diluted shares	145.1M shares
Fully diluted market cap	$2,387.8M
Cash per share	$0.34
Quarterly burn	+$52.6M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

133.1M

Pre-funded warrants

0.0M

Options

5.8M

RSUs

4.7M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.5M

FDSO

145.1M

Cap table as of 2026-06-30.

Price history

Loading AUPH daily closes…

Loading price history…

Next catalyst

Aritinercept · Apr 13 - May 25 in 30 mo · Phase 2 · Myasthenia Gravis, Generalized

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 13 - May 25 in 30 mo	Aritinercept	Phase 2	Myasthenia Gravis, Generalized	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LUPKYNIS

Approved · Active Modality: calcineurin inhibitor (CNI) immunosuppressant

Aliases voclosporin

Target calcineurin

Partnerships Otsuka Pharmaceutical: collaboration and licensing (Dec 2020) to develop/commercialize oral voclosporin in Japan, EU, UK, Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein, Ukraine; commercial supply agreement (Aug 2022)

Indications

Active lupus nephritis (adult) (Approved)

Status note First FDA-approved oral therapy for active LN (Jan 2021). PRESERVE Phase 4 study initiated: LUPKYNIS plus belimumab, obinutuzumab or anifrolumab in LN.

aritinercept

Phase 1 · Active Modality: dual BAFF/APRIL inhibitor (BCMA-engineered binding domain, IgG4 Fc)

Target BAFF and APRIL

Indications

Autoimmune diseases (four indications; not named in filing) (Phase 1)

Status note Acquired via Kezar Life Sciences acquisition (completed May 11, 2026). Clinical development initiated in four potential indications. Clinical study in one autoimmune disease initiated; additional study planned in H1 2026.

AUR300

Stage not disclosed · Terminated

Status note Discontinued in Feb 2024 strategic restructuring (headcount reduced ~25%).

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	LUPKYNIS
Lead indication	Lupus Nephritis
Lead phase	Phase 4
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07596901	Phase 2	Recruiting	Sponsor	AUPH	—	Myasthenia Gravis, Generalized	—
NCT07611214	Not disclosed	Recruiting	Sponsor	AUPH	—	Lupus Nephritis	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Aurinia Pharmaceuticals Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	13,044,106	+814,606	10.05%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

AUPH — Aurinia Pharmaceuticals Inc ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

AUPH — Aurinia Pharmaceuticals Inc